Sionna Therapeutics, Inc.
Clinical trials sponsored by Sionna Therapeutics, Inc., explained in plain language.
A biotech developing treatments for cystic fibrosis.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New combo pill aims to boost cystic fibrosis treatment
Disease control CompletedThis study tests whether adding a new drug called SION-719 to the standard CF medication Trikafta is safe and helps people with cystic fibrosis who have two copies of the F508del mutation. Sixteen participants will receive either SION-719 or a placebo alongside their usual Trikaf…
Phase 2 • Sponsor: Sionna Therapeutics Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New CF drug cocktail enters first human safety tests
Disease control CompletedThis early-stage trial tests the safety of three experimental drugs (SION-451, SION-2222, and SION-109) given together to healthy adults aged 18–55. The study aims to see if the combinations are safe and how the body processes them. It is a first step toward possibly developing a…
Phase 1 • Sponsor: Sionna Therapeutics Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC